Trial Profile

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amezalpat (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; IO-108 (Primary) ; Muzastotug (Primary) ; NKT 2152 (Primary) ; Tiragolumab (Primary) ; Tobemstomig (Primary) ; Tocilizumab (Primary)
Indications Liver cancer
Focus Therapeutic Use
Acronyms Morpheus-Liver
Sponsors Roche

02 Feb 2026 Planned End Date changed from 31 Dec 2026 to 31 Dec 2027.
02 Feb 2026 Planned primary completion date changed from 31 Dec 2026 to 31 Dec 2027.
28 Feb 2025 According to a Immune-Onc Therapeutics media release, company is expected to enroll 40 patients across 25 sites worldwide in the IO-108-containing arm.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com